Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 736,633 shares of RXRX, which is worth approximately $5.75 Million. The most recent transaction as insider was on Mar 07, 2022, when has been sold 300,000 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 737K

3.41% 3M change

6.96% 12M change

Total Value Held $5.75 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 07 2022	BUY Conversion of derivative security	-	300,000 Added 35.97%	534,020 Class A Common Stock
Feb 22 2022	SELL Open market or private sale	$1,022,000 $10.22 p/Share	100,000 Reduced 29.94%	234,020 Class A Common Stock
Feb 22 2022	BUY Conversion of derivative security	-	100,000 Added 23.04%	334,020 Class A Common Stock
Feb 04 2022	SELL Payment of exercise price or tax liability	$3,910 $11.4 p/Share	343 Reduced 0.15%	234,020 Class A Common Stock
Feb 04 2022	BUY Grant, award, or other acquisition	-	210,893 Added 47.36%	234,363 Class A Common Stock
Jan 31 2022	SELL Open market or private sale	$232,934 $11.73 p/Share	19,858 Reduced 45.83%	23,470 Class A Common Stock
Jan 31 2022	BUY Conversion of derivative security	-	19,858 Added 31.43%	43,328 Class A Common Stock
Jan 14 2022	SELL Open market or private sale	$3,446,780 $13.57 p/Share	254,000 Reduced 91.54%	23,470 Class A Common Stock
Jan 14 2022	BUY Conversion of derivative security	-	254,000 Added 47.79%	277,470 Class A Common Stock
Jan 13 2022	SELL Open market or private sale	$1,271,070 $14.61 p/Share	87,000 Reduced 78.75%	23,470 Class A Common Stock
Jan 13 2022	BUY Conversion of derivative security	-	87,000 Added 44.06%	110,470 Class A Common Stock
Dec 16 2021	SELL Open market or private sale	$4,000 $20.0 p/Share	200 Reduced 0.84%	23,470 Class A Common Stock
Dec 16 2021	BUY Conversion of derivative security	-	200 Added 0.84%	23,670 Class A Common Stock
Dec 13 2021	SELL Open market or private sale	$2,002 $20.02 p/Share	100 Reduced 0.42%	23,470 Class A Common Stock
Dec 13 2021	BUY Conversion of derivative security	-	100 Added 0.42%	23,570 Class A Common Stock
Dec 09 2021	SELL Open market or private sale	$21,731 $20.01 p/Share	1,086 Reduced 4.42%	23,470 Class A Common Stock
Dec 09 2021	BUY Conversion of derivative security	-	1,086 Added 4.24%	24,556 Class A Common Stock
Dec 08 2021	SELL Open market or private sale	$214,880 $20.15 p/Share	10,664 Reduced 31.24%	23,470 Class A Common Stock
Dec 08 2021	BUY Conversion of derivative security	-	5,488 Added 15.93%	28,958 Class A Common Stock
Dec 08 2021	BUY Exercise of conversion of derivative security	$70,756 $2.47 p/Share	28,646 Added 50.0%	28,646 Class A Common Stock
Dec 07 2021	SELL Open market or private sale	$345,840 $20.75 p/Share	16,667 Reduced 0.2%	8,201,216 Class B Common Stock
Nov 21 2021	SELL Bona fide gift	-	1,100,000 Reduced 11.81%	8,217,883 Class B Common Stock
Apr 20 2021	SELL Other acquisition or disposition	-	9,317,883 Reduced 100.0%	0 Common Stock
Apr 20 2021	BUY Conversion of derivative security	-	55,383 Added 0.59%	9,317,883 Common Stock
Apr 20 2021	BUY Other acquisition or disposition	-	9,317,883 Added 50.0%	9,317,883 Class B Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account